tolebrutinib

News

Data builds on Roche's dominance in primary progressive MS

Roche looks on track to add oral BTK inhibitor fenebrutinib to treatment options for primary progressive multiple sclerosis.

News

Man looking through red lenses of binoculars

11 high-impact drugs to look out for in 2026

Medicines for obesity, diabetes, rare diseases, cancer, and women's health feature among Clarivate's annual round-up of 11 Drugs to Watch this year.

News

No Christmas present for Sanofi, as FDA turns down MS drug

FDA has turned down Sanofi's oral BTK inhibitor tolebrutinib for multiple sclerosis, despite suggesting earlier it would delay a decision until 2026.

News

Sanofi gets double blow for MS drug tolebrutinib

Shares in Sanofi have slid on a double dose of bad news for its oral BTK inhibitor tolebrutinib, in development as a therapy for multiple sclerosis.

News

FDA starts review of Sanofi's MS hope tolebrutinib

Sanofi's oral BTK inhibitor tolebrutinib is heading towards an FDA decision in September as a potential treatment for multiple sclerosis.

News

Sanofi's tolebrutinib cuts MS progression by 31% in trial

Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data

Data builds on Roche's dominance in primary progressive MS

11 high-impact drugs to look out for in 2026

No Christmas present for Sanofi, as FDA turns down MS drug

Sanofi gets double blow for MS drug tolebrutinib

FDA starts review of Sanofi's MS hope tolebrutinib

Sanofi's tolebrutinib cuts MS progression by 31% in trial

NHS "isn't delivering equitable care for rare diseases"

Using AI-driven synthetic personas to take your insights fur...

tolebrutinib

Editor's Picks